## U.S. NUCLEAR REGULATORY COMMISSION

## **MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.								
1.	Licer Kaiser Permanente	""	accordance with letter dated eptember 10, 2020,	4. Expiration Date: February 29, 2036				
2.	1396 Piccard Drive Rockville, MD 20850	2	License No.: 19-31420-01 is renewed in its entirety to read as follows:	- 5. Docket No.: 030-38361 Reference No.:				
6.	Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that license may possess at any one timunder this license					
A.	Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CF 35.100.	₹R			
B.	Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200	١.			
C.	lodine-131 permitted by 10 CFR 35.300	C. Any	C. 350 millicuries total	C. For any use permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.				
l								

	374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE 2 OF 3 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET  License No.: 19-31420-01  Amendment No. 5  Docket or Reference No.: 030-38361	MATERIALS LICENSE			

## **CONDITIONS**

- 10. Licensed material shall be used or stored at the licensee's facilities located at: Ground Level, Kaiser Permanent Capitol Hill Medical Center, 700 Second Street NE, Washington, District of Columbia, 20002
- 11. The Radiation Safety Officer (RSO) for this license is Arnold Able.
- 12. Licensed material shall only be used by, or under the supervision of:
  - A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
  - B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)	Material and Use
Carol P. Cardinale, M.D.	10 CFR 35.100,10 CFR 35.200
Vincent Q. Dam, M.D.	Oral administration of sodium iodide I-131.
Howard DiPiazza, M.D.	10 CFR 35.100,10 CFR 35.200
Seyed Emamian, M.D.	10 CFR 35.100,10 CFR 35.200
Yaning Liu, M.D.	10 CFR 35.100,10 CFR 35.200
Philipose G. Mulugeta, M.D.	10 CFR 35.100,10 CFR 35.200; Oral administration of sodium iodide I-131
David Orange, M.D.	10 CFR 35.100,10 CFR 35.200; Oral administration of sodium iodide I-131
Trushar M. Sarang, M.D.	10 CFR 35.100,10 CFR 35.200; Oral administration of sodium iodide I-131

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit in 10 CFR 30.35(d) for which decommissioning financial assurance is required.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE 3 OF 3 PAGES
MATERIALS LICENSE	License No.: 19-31420-01	Docket or Reference No.: 030-38361	
SUPPLEMENTARY SHEET	Amendment No. 5		
<ul> <li>14. Except as specifically provided otherwise representations, and procedures contained those statements, representations, and publicense condition does not limit the license. The U.S. Nuclear Regulatory Commission licensee's application and correspondence regulations.</li> <li>A. Application dated August 4, 2020 [ML2]</li> <li>B. Letter dated January 22, 2021 [ML210]</li> <li>C. Letter dated February 2, 2021 [ML210]</li> </ul>	ed in the documents, including any enclorocedures that are required to be submittee's ability to make changes to the radian's regulations shall govern unless the size impose on the licensee requirements (20282A406)	osures, listed below. This license itted in accordance with the regulation protection program as provistatements, representations, and	e condition applies only to lations. Additionally, this ded for in 10 CFR 35.26. procedures in the
	FOR	THE U.S. NUCLEAR REGULAT	ORY COMMISSION
Date: February 4, 2021		Tara Weidner Region 1	